Related Experiment Video
Updated: Jun 27, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Prise en charge of metastatic renal carcinoma]
1Service d'Urologie, Université Paris Descartes, France. arnaud.mejean@nck.aphp.fr
Abstract:
Metastatic renal carcinoma concerns 30 to 50% of patients. The principal localisations are lung, liver, bone and brain. In case of unique localisation the treatment is almost surgical whatever the organ may be with sometimes long remissions. In case of many localisations, targeted therapy is the gold standard of treatment in first or second line. In France, today, 4 drugs are currently approved (sunitinib, sorafenib, temsirolimus, bevacizumab). Because of a poor prognosis trials testing combination of therapies are required to benefit patients. At least nephrectomy is necessary looking forward prospective studies to estimate its real impact.
Insights
Metastatic renal carcinoma affects many patients, with treatments varying by spread. Targeted therapy is standard for widespread cancer, but combination therapies are needed for better outcomes.
Area of Science:
- Oncology
- Nephrology
- Medical Research
Context:
- Metastatic renal carcinoma presents in 30-50% of patients.
- Common metastatic sites include the lungs, liver, bone, and brain.
- Treatment strategies differ based on the extent of metastasis.
Purpose:
- To outline current treatment standards for metastatic renal carcinoma.
- To highlight the need for advanced therapeutic approaches.
- To emphasize the importance of ongoing clinical trials and research.
Summary:
- Surgical intervention is often curative for single metastatic sites.
- Targeted therapy is the established first- and second-line treatment for widespread disease.
- Four targeted drugs (sunitinib, sorafenib, temsirolimus, bevacizumab) are approved in France.
- Poor prognosis necessitates trials exploring combination therapies.
- The role of nephrectomy requires further investigation through prospective studies.
Impact:
- Informs clinical decision-making for metastatic renal carcinoma management.
- Drives research into novel combination therapies for improved patient survival.
- Highlights the need for continued investigation into surgical and systemic treatment efficacy.
